News
Market and company headlines
Intuitive Surgical, Inc. (ISRG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

For questions about this article or underlying research, email help@trefis.com.

Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

2026-10-23. The following slide deck was published by Intuitive Surgical, Inc.

Key TakeawaysIntuitive Surgical shares fell 6% today after U. S.

For questions about this article or underlying research, email help@trefis.com.

Intuitive Surgical stock came into Thursday with strong recent momentum, then slipped about 2% after the market had its first clean look at Q3 2026 numbers. The initial reaction focused on the headline gap between rich expectations and reality. The company delivered roughly US$3.0b in quarterly revenue and about US$1.50 in basic earnings per share, solid figures for a surgical robotics leader but less thrilling next to a P/E multiple above 50x. Short-term traders are fixated on that...
Intuitive Surgical (ISRG) and Elevance Health (ELV) delivered impressive Q3 earnings beats, making both healthcare stocks worth considering as their growth outlooks improve.

Medical technology company Intuitive Surgical (NASDAQ:ISRG) beat Wall Street’s revenue expectations in Q3 2026, with sales up 21.7% year on year to $3.05 billion. Its non-GAAP profit of $3 per share was 13.6% above analysts’ consensus estimates.

Intuitive Surgical stock tumbled Wednesday as elevated expectations from the buy-side hampered the solid third-quarter report.

Intuitive Surgical (ISRG) will face potential risks to its 2027 procedure momentum from pricing acti

Resolving a major litigation settlement while expanding into cost-sensitive outpatient centers positions the company for sustained procedure growth.

Revenue hit $3.05 billion as procedure volumes surged and system placements accelerated.

ISRG's Q3 2026 earnings beat estimates as strong system placements, rising procedure volumes and improving margins fuel double-digit revenue growth.

Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

Evercore ISI Group analyst Vijay Kumar maintains Intuitive Surgical (NASDAQ:ISRG) with a In-Line and lowers the price target from $400 to $385.

Intuitive Surgical (NASDAQ:ISRG) shares declined 7. 5% to $404.

Intuitive Surgical (ISRG:NASDAQ) shares fell about 7% in after-hours trading on Tuesday (to about $406) after the company’s third-quarter report showed U. S.

Intuitive Surgical (NASDAQ:ISRG) reported third-quarter 2026 revenue growth of 22% to just over $3 billion as procedure growth, system placements and adoption of newer platforms supported results. The company said 84% of quarterly revenue was recurring revenue, while non-GAAP earnings per share rose

The headline numbers for Intuitive Surgical (ISRG) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Intuitive Surgical, Inc. (ISRG) Q3 2026 Earnings Call October 20, 2026 4:30 PM EDTCompany ParticipantsDaniel Connally - VP & Head of Investor...

Intuitive Surgical beat quarterly estimates but disclosed an antitrust settlement and narrowed its procedure-growth forecast.

Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +14.94% and +5.84%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (NASDAQ:ISRG) is making robotic surgery easier for hospitals to finance. Operating leases accounted for 54% of second-quarter da Vinci placements, up from 49% a year earlier. Lower upfront commitments can expand adoption, but shareholders fund equipment before collecting its lifetime returns. Intuitive Surgical, Inc. (NASDAQ:ISRG) trades at 33x forward P/E and 46x […]

Intuitive Surgical plans to extend instrument life in 2027, trading near-term revenue per procedure for lower surgical costs and broader robotic surgery adoption.
Robotic surgery is growing, procedures are climbing, and da Vinci 5 is rolling out. Is Intuitive Surgical's premium valuation worth paying?

Intuitive Surgical has rebounded from recent lows, with double-digit sales growth projected and potential 43% upside as its robotic surgery business expands.

Intuitive Surgical stock earns a Zacks Rank #2 (Buy) and looks poised for a potential technical breakout as it overtakes vital long-term levels heading into its Q3 earnings release on October 20.

Intuitive Surgical, Inc. (NASDAQ:ISRG) is underperforming the broader market, with shares declining by nearly 24% since the start of 2026. That underperformance is notable for investors because Intuitive’s operating performance has remained strong, and the company’s latest results show continued double-digit growth in procedures, revenue, and its installed base of surgical systems. The question for […]
Intuitive Surgical has rewarded patient shareholders over the past few years. With the share price at US$427.86 and fresh competition emerging, the real issue is whether that valuation is still grounded in the cash the business can generate. Over the past 3 years the stock has gained 56.5%. This puts real pressure on the question of how far its future cash flows can stretch to support that climb. Johnson & Johnson's FDA cleared OTTAVA system introduces a new rival in robotic surgery. This...

Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 10 years by 5.33% on an annualized basis producing an average annual return of 19.01%. Currently, Intuitive Surgical has a market capitalization
Intuitive Surgical, Inc. (ISRG) reached $427.86 at the closing of the latest trading day, reflecting a +1.81% change compared to its last close.

Evaluate the expected performance of Intuitive Surgical (ISRG) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Intuitive Surgical shares have surged nearly 12% in a month ahead of Q3 earnings. Strong da Vinci 5 adoption and Ion growth fuel momentum, but valuation and risks linger.

Chipotle, BP and Intuitive Surgical stand out as sales growth stocks to watch, with 2026 revenue forecasts ranging from 9% to 28.9% as Q3 earnings begin.

Intuitive Surgical, Inc. (NASDAQ:ISRG) more or less invented modern robotic surgery with its da Vinci system, and for two decades it had the field to itself. The stock has now fallen about 35% from its high to roughly $395, yet it still trades near 46 times earnings and at $140 billion in value. So here […]

Intuitive Surgical, Inc. is a Buy: recurring revenue, solid cash flow, da Vinci 5 upgrades, & margins outlook support a $689.75 targetâclick to read more on ISRG.

Intuitive Surgical (ISRG) grows faster and earns a higher operating margin than any of the five rivals in its health care peer group. It is also the most expensive of the six when price is measured against earnings. It holds that place even after its stock fell 10.3% over the past twelve months. How much more do you pay for a dollar of Intuitive's earnings than for a dollar of a rival's.


Intuitive Surgical is beating estimates and raising margins while its installed base keeps expanding. Abbott is executing steadily across a diversified portfolio but growing at a more measured pace.

Analysts think this beaten-down healthcare stock will rebound.

Intuitive Surgical is expected to announce its third-quarter earnings in October, and Wall Street expects the company’s EPS to increase by a single-digit percentage.

Tesla’s Optimus is chasing general-purpose robotics, but Intuitive Surgical shows how specialized robots can build massive businesses.

The market may be underestimating these companies.
Earlier this month, Intuitive Surgical received CE mark approval for using its da Vinci SP single-port robotic system in transvaginal gynecologic procedures, adding to its existing approvals for a range of endoscopic and natural-orifice surgeries across Europe. This world's-first indication for the SP platform deepens Intuitive’s position in minimally invasive, scarless surgery by broadening its clinically supported use in complex anatomical spaces. We’ll now examine how this expanded...


Intuitive Surgical's Q3 earnings call highlights instrument price cuts to boost robotic surgery adoption, higher 2026 margins and slowing U.S. procedure growth.

(Updates with the stock move, outlook, and the legal charge in the headline, first and last two para

Medical technology company Intuitive Surgical (NASDAQ:ISRG) beat Wall Street’s revenue expectations in Q3 2026, with sales up 21.7% year on year to $3.05 billion. Its non-GAAP profit of $3 per share was 13.6% above analysts’ consensus estimates.



